These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2073222)

  • 41. [The comparative efficacy of Aurorix and amitriptyline in treating depressions].
    Iakovlev VA
    Voen Med Zh; 1997 Apr; 318(4):37-8. PubMed ID: 9221592
    [No Abstract]   [Full Text] [Related]  

  • 42. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.
    Versiani M; Amrein R; Stabl M
    Int Clin Psychopharmacol; 1997 Jul; 12(4):183-93. PubMed ID: 9347378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
    Laux G; Beckmann H; Classen W; Becker T
    J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.
    Bougerol T; Uchida C; Gachoud JP; Köhler M; Mikkelsen H
    Psychopharmacology (Berl); 1992; 106 Suppl():S102-8. PubMed ID: 1546121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Moclobemide (Aurorix) in primary major depression.
    Rihmer Z; Barsi J; Vad G; György S; Zalay B; Vég K; Gábor A
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):367-72. PubMed ID: 8208985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Australian multicentre moclobemide trial.
    Stanton J
    Aust N Z J Psychiatry; 1993 Mar; 27(1):158. PubMed ID: 8481158
    [No Abstract]   [Full Text] [Related]  

  • 47. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study.
    Orsel Donbak S; Turkçapar MH; Ozturk Kiliç EZ; Demirergi N; Akdemir A; Sirin A; Ozbay MH
    Acta Psychiatr Belg; 1995; 95(3):139-51. PubMed ID: 8525856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.
    Hebenstreit GF; Loidl M; Baumhackl U; Gallhofer B; Geretsegger C; Radmayr E; Saletu M; Schöny W; Stabl M
    J Neural Transm Suppl; 1990; 32():177-84. PubMed ID: 2089087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moclobemide compared with second-generation antidepressants in elderly people.
    De Vanna M; Kummer J; Agnoli A; Gentili P; Lorizio A; Anand R
    Acta Psychiatr Scand Suppl; 1990; 360():64-6. PubMed ID: 2248077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group.
    Lecrubier Y; Pedarriosse AM; Payan C; Schmid-Burgk W; Stabl M
    Acta Psychiatr Scand; 1995 Oct; 92(4):260-5. PubMed ID: 8848950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months.
    Gagiano CA; Müller FG; de Kock RF; Schall R
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):46S-50S. PubMed ID: 7593731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moclobemide and placebo in mild major depression: a double-blind randomized trial.
    Ose E; Holm P
    Psychopharmacology (Berl); 1992; 106 Suppl():S114-5. PubMed ID: 1546122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
    Casacchia M; Carolei A; Barba C; Frontoni M; Rossi A; Meco G; Zylberman MR
    Pharmacopsychiatry; 1984 Jul; 17(4):122-5. PubMed ID: 6382361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.
    Stabl M; Kasas A; Blajev B; Bajetta G; Zöchling R; Holsboer-Trachsler E; Realini R; Schäublin-Loidl M
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):41S-45S. PubMed ID: 7593730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
    Versiani M; Nardi AE; Mundim FD; Alves AB
    J Neural Transm Suppl; 1989; 28():65-75. PubMed ID: 2794994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antidepressants, alcohol and psychomotor performance.
    Tiller JW
    Acta Psychiatr Scand Suppl; 1990; 360():13-7. PubMed ID: 2248062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.
    Pancheri P; Delle Chiaie R; Donnini M; Seripa S; Gambino C; Vicario E; Trillo L
    Clin Neuropharmacol; 1994; 17 Suppl 1():S58-73. PubMed ID: 7954485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.